Twist Bioscience Launches $250M Underwritten Public Offering, Adding to Recent ATM Program
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience has launched a $250 million underwritten public offering of common stock, with a $37.5 million overallotment option, adding to its recently established $200 million ATM program. The offering comes amid a Q3 net loss and ongoing insider selling.
Updates
· SEC 8-K — Underwriters exercised their option to purchase all 468,750 additional shares at $96.00, bringing total shares to 3,593,750 and expected net proceeds to approximately $327.1 million.
· BusinessWire — Twist Bioscience upsized the offering to 3.125 million shares priced at $96.00, raising $300 million, a 20% increase from the initially announced $250 million. Underwriters have a 30-day option for an additional 468,750 shares.
Key Events · Financing and Capital Events · TWST
-
$250M Underwritten Offering Launched
Twist Bioscience is offering $250 million of common stock in a firm commitment underwritten public offering, with a 30-day option for underwriters to purchase up to an additional $37.5 million.
-
Pricing at Discount to Market
The offering price will be set at a discount to the last reported sale price of $101.06 on August 3, 2026; final pricing and dilution will be determined at pricing.
-
Use of Proceeds
Net proceeds will fund R&D investments, manufacturing capacity expansion, product offerings, and general corporate purposes, with management retaining broad discretion.
-
Follows Recent ATM Program
This offering comes just weeks after the company established a $200 million at-the-market program on June 18, 2026, under which no shares have been sold to date.
Analysis · TWST · Life Sciences
Twist Bioscience is tapping public markets for $250 million via an underwritten common stock offering, just weeks after establishing a $200 million at-the-market program. The offering, led by Goldman Sachs, William Blair, Leerink Partners, and Guggenheim Securities, includes a 30-day option for underwriters to purchase an additional $37.5 million. Proceeds are earmarked for R&D, manufacturing expansion, and general corporate purposes. The offering price will be set at a discount to the last reported sale price of $101.06 on August 3, 2026, and the exact dilution will depend on final pricing. This move follows a Q3 net loss of $35.1 million and a pattern of insider selling, raising questions about near-term cash needs and shareholder dilution.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $97.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $23.30 to $106.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.